Balloon cells (BCs) are the pathologic hallmark of focal cortical dysplasia type IIB, a common cause of pharmacoresistent epilepsy. Expression of markers of cell immaturity and of the proliferation marker minichromosome maintenance protein 2 (mcm2) have been previously shown in BCs, suggesting that these cells might represent a pool of less-differentiated cells licensed for replication. An alternative explanation is that these cells are the remnants of early cortical plate cells that have failed to differentiate or to be eliminated during development and are arrested in the cell cycle, a hypothesis that this study aims to explore. Using immunohistochemical methods and semiquantitative analysis in 19 cases of focal cortical dysplasia (ages 1Y81 years), we studied the expression of cell cycle proteins important either in regulating progression through the G 1 phase or inducing cell arrest and promoting premature senescence. Only a small fraction of BCs expressed geminin, suggesting that few BCs enter the S phase or complete the cell cycle. Variable expression of nonphosphorylated retinoblastoma protein (Rb), cdk4, and p53 was noted in BCs. Cyclin E, D1, cdk2, phosphorylated Rb (795 and 807/ 811), and checkpoint 2 expression levels were low in BCs. These findings suggest early rather than late G 1 arrest. Cell senescence could be induced by an undefined cerebral insult during development or alternatively represent a physiologic replicative senescence. These findings also suggest that dysregulation of cell cycle pathways may occur in focal cortical dysplasia, which opens further areas for exploration as potential new treatment avenues.
INTRODUCTION
The presence of balloon cells (BCs) is a defining and striking pathologic feature of type IIB focal cortical dysplasia (FCD), a malformation of cortical development commonly observed in patients with focal epilepsy undergoing surgery (1, 2) . Recent studies of BCs in resected surgical tissues from patients with epilepsy have shown expression of a range of stem cell markers, including CD34, CD133, and nestin, reflecting the immature status of BCs (3Y5). These findings could suggest either ongoing postnatal neuronal and glial genesis or the fact that these cells are Barrested[ in the early stages of cortical development. For example, the recently proposed Bdysmature cerebral developmental hypothesis[ of cortical dysplasia (1) suggests that based on cell morphology, quantitative studies, and electrophysiologic characteristics, BCs represent radial glial cells that have failed to undergo postnatal degeneration; whereas dysmorphic neurons within FCD represent immature neurons and interneurons, the remnants of early subplate cells that have also been selectively retained.
We have previously demonstrated that the majority of BCs in FCD lesions showed nuclear immunopositivity for mini-chromosome maintenance protein 2 (mcm2) (4) . Mcm2 is expressed through the cell cycle in G 1 /S/G 2 and M phases, but not in G 0 (quiescence). Our findings suggested that BCs are licensed for replication, retaining the capacity for cell division. We also noted very few cells in a proportion of FCD cases labeled for the proliferation marker Ki67. The difference in mcm2 and Ki67 immunoreactivity suggests that only a small fraction of BCs actually progress through the cell cycle. One possible explanation is that BCs are in a state of cell cycle arrest due to unknown factor(s) interfering with the normal signals orchestrating cell division.
Expression of cell cycle proteins, including geminin and the cyclins, is tightly regulated and closely linked with cell growth and differentiation. Many cell cycle proteins also have roles in neuronal specification (6) . In addition, in terminally differentiated neurons, the re-expression of cell cycle proteins may initiate neuronal cell death and apoptosis (7, 8) . All of these processes may be relevant to the pathologic origins of and any progressive changes seen in FCD.
Previous molecular studies of BCs in FCD by other groups have indicated that alteration in cell signalling pathways important in cell growth and development can also influence cell cycle protein regulation (9Y11). The aim, therefore, of the present study was to examine the expression of cell cycle proteins known to have important regulatory activity in the progression of G 1 phase and to investigate the possibility of cell cycle arrest in BCs. Cell cycle arrest or induced senescence in BCs in FCD could account for the immature phenotype, cell hypertrophy, and high levels of mcm2 in BCs and potentially explain the failure of these cells to be eliminated during development.
MATERIALS AND METHODS

Case Selection
Nineteen cases of FCD type IIB (FCDIIB) were included from the neuropathology archives at the National Hospital for Neurology and Neurosurgery, London, with additional cases from neuropathology departments of Great Ormond Street Hospital and the Radcliffe Infirmary, Oxford. The study was approved by the local ethical committee. In 17 cases the patients had undergone therapeutic surgical resections of the FCD for the treatment of refractory epilepsy and in the 2 older cases the tissue was obtained postmortem from patients with long histories of focal seizures. The age range of the study group was 1 to 81 years (mean age = 26.5 years) ( Table 1) . In 1 case a clinical diagnosis of tuberous sclerosis was suspected but not confirmed (case 1). In another case (case 2) extensive hemispheric changes were seen on magnetic resonance imaging. Lesion localization and lobar involvement are detailed in Table 1 . Cases were selected to include those with larger resections with adjacent normal cortex; cases comprising small, poorly orientated specimens with limited representations of BCs were not included.
Control Groups
Comparison and control studies for the cell cycle antibodies were as follows. We studied a series of 6 normal brains obtained at postmortem (spanning ages 37 weeks to 15 months) to compare the expression of cell cycle proteins in the frontal cortex, temporal cortex, white matter, and periventricular region in normal postnatal development. In addition, surgically resected temporal lobe specimens without neuropathologic changes from 3 adult patients without epilepsy (specimens removed for the treatment of acute raised intracranial pressure after trauma) were included (ages 27, 33, and 47 years). Epilepsy controls to compare for the effects of seizures on cell cycle protein expression included surgical temporal neocortex adjacent to hippocampal sclerosis but without evidence of cortical dysplasia; both pediatric patients (n = 5, mean age 8.65 years; age range 0.25Y17 years) and adult patients (n = 2, ages 35 and 42 years) were included to compare to the broad age range in FCD cases. All of the patients with epilepsy had received antiepileptic drug medication similar to patients with FCD and had undergone surgery for alleviation of refractory seizures. In addition, we were able to compare expression in the FCD region with the adjacent normal cortex as a further internal control. 
Immunohistochemistry
In all cases a single block representative of the FCD was selected from each case and further sections were cut at 5 and 20 Km. Tissue fixation times were between 2 and 7 days for surgical cases and up to 5 weeks for the adult postmortem cases. Thick sections were stained with cresyl violet/Luxol Fast Blue and studied using immunohistochemistry for neuronal nuclear protein, glial fibrillary acidic protein (GFAP), phosphorylated and nonphosphorylated neurofilaments, nestin, and CD34, using routine methods for the Thom purpose of delineating the boundaries as well as confirming the subtype of FCD (2). For the cell cycle studies, 7-Km paraffin-embedded sections were dewaxed, rehydrated through graded alcohols, and taken to water. Sections were microwaved with antigen retrieval solution followed by primary antibody incubation as detailed in Table 2 . Labeling was detected by EnVision (Dako, Glostrup, Denmark). Staining was visualized with NovaRED from Vector Laboratories (Burlingame, CA). Nuclei were counterstained with hematoxylin. Positive control tissues for all antibodies included glioblastoma multiforme. Negative controls were treated identically except that the primary antibody was replaced with normal immunoglobulin IgG.
Double-Labeled Fluorescence Immunohistochemistry
In 4 cases (cases 1, 4, 13, and 16) double immunofluorescence for GFAP combined with cdk4, p53, retinoblastoma protein (Rb) (4H1), or geminin 95 was performed. Seven-micrometer paraffin-embedded sections were dewaxed, rehydrated through graded alcohols, and taken to water. Sections were microwaved for 15 minutes in Vector Antigen Retrieval Solution and cooled for 20 minutes and then were incubated with polyclonal antibodies to GFAP (1:400) and geminin 95 (1:300) overnight at 4-C, followed by incubation with an equal mixture of Alexa Fluor 594 chicken anti-rabbit (1:200) and Alexa Fluor 488 goat anti-mouse (1:200; Invitrogen, Carlsbad, CA) overnight at 4-C. The tyramide signal amplification method was used for monoclonal antibodies against Rb(4H1), cdk4, and p53. Endogenous peroxidase was quenched in 3% hydrogen peroxide in deionized water followed by microwaving. Normal horse serum was used for protein blocking followed by incubation of polyclonal GFAP (1:400) with each monoclonal antibody listed above (the same dilution as in Table 2 ) overnight at 4-C. For monoclonal antibodies, sections were incubated with Vector anti-mouse ImmPRESS followed by tyramide signal amplification fluorescein (PerkinElmer Life and Analytical Sciences, Boston, MA). Sections were incubated with Alexa Fluor 594 chicken anti-rabbit for 1 hour and then were washed and mounted with Prolong Gold with 4,6-diamidino-2-phenylindole (Invitrogen). Between each step of staining sections were washed with PBS plus 0.05% Tween 20. Negative controls were treated in the same way except that primary antibodies were omitted. Sections were visualized with a Zeiss LSM 510 Meta laser confocal microscope.
Analysis
The sections were evaluated semiquantitatively for the labeling of BCs in the cortex and the white matter of each section with each antibody and scored as follows: +, occasional or rare single positive BCs; ++, small numbers of positive BCs; +++, frequent positive BCs (approximately half of BCs labeling in the section); and ++++, majority of BCs positive. The localization of labeling, whether in the nuclear or cytoplasmic compartment, was noted. Immunoreactivity was also assessed in the dysmorphic and hypertrophic neuronal component (DN) of the FCD, in the adjacent cortex, and in all control cases.
RESULTS
For all cell cycle markers the positive control tissue of glioblastoma showed nuclear labeling in a variable proportion of the proliferating tumor cells. The result of the semiquantitative analysis in FCD cases is detailed in Table 3 together with description of staining patterns in adjacent cortex. A description of the collective main findings is given below.
Mini-Chromosome Maintenance Protein
Twelve of the 19 cases studied (cases 1Y6, 8, 9, 13, 14, 18, and 19) were previously included in our analysis of mcm2 immunoreactivity (4). Immunohistochemistry for mcm2 on the additional 7 cases included here confirmed previous results, with the majority of BCs demonstrating strong nuclear staining (Figs. 1A, 2A, 3 ).
Geminin
Immunohistochemistry for geminin was performed with 2 previously characterized antibodies (G95 and G94) from Prof. G. Williams, University College London (12) . Both showed similar staining patterns and results (Table 3) . Geminin-immunopositive BC nuclei were infrequently identified in FCD, present in only 6 cases, and more often in cases younger than 12 years old than in adult cases (Figs. 1B, C, 2B, 3) . The positive cells, when present, were of small glial and possible microglial cells in the white matter labeled for geminin; no neuronal staining was observed.
Retinoblastoma Protein
Nuclear labeling for active, nonphosphorylated Rb was observed in a large proportion of the BCs in the FCD cases studied (Figs. 1K, 2E, 3) . The 3 cases with absence of Rbpositive BCs were aged 52 years or older. Labeling was also noted in nuclei of DNs and hypertrophic neurons in the region of dysplasia. Adjacent cortex showed less intense and less frequent neuronal labeling. BCs showed little labeling with antiphosphorylated Rb antibodies, specific for either 807/811 or 795 phosphorylation sites, with occasional nuclear labeling in only 5 cases each, with a wide age range (Table 3 ; Fig. 1L , O). DNs were generally immunonegative for phospho-Rb antibodies; there was rare phospho-Rb cytoplasmic labeling in only 2 cases. The adjacent cortex showed no phospho-Rb labeling of pyramidal neurons, but scattered small glial cells were immunopositive. Control pediatric and adult temporal lobe cases from patients with refractory epilepsy and adult nonepilepsy temporal lobe showed occasional labeling of small glial cells in all groups for nonphosphorylated Rb and weak nuclear labeling of a proportion of cortical pyramidal neurons in the pediatric epilepsy controls. Phosphorylated Rb antibody staining showed very occasional labeling of white matter glial cells in all control groups with nuclear labeling of some pyramidal cortical neurons in the pediatric epilepsy series.
Cyclin E and D
Cyclin E immunohistochemistry in FCD showed, in general, a striking absence of labeling of BC nuclei (Fig. 1I) ; single, weak, positive BCs were present in only 5 cases. DNs showed more frequent and intense positive nuclear labeling of a proportion of cells (Table 3 ; Fig. 1D ). The adjacent cortex and control tissues showed more numerous positive small glial cells and weaker labeling of some pyramidal and white matter neurons as previously noted (13) . Cyclin D1 similarly showed only infrequent and weak cytoplasmic labeling of BCs in 2 cases. There was no convincing labeling of DNs (Fig. 1G) . As in previous studies, cyclin D1 showed labeling of small neuronal satellite cells and oligodendroglia in the cortex and in the white matter with both nuclear and cytoplasmic labeling in both FCD regions and adjacent cortex (14) . There was an impression of greater numbers of these small positively labeled cells in the region of dysplasia (Fig. 1G, H) . Control pediatric and adult temporal lobe cases from patients with refractory epilepsy and adult nonepilepsy temporal lobe showed nuclear staining in a proportion of white matter glial cells for cyclin D and weak nuclear staining of some cortical pyramidal cells, which was more pronounced in pediatric epilepsy cases.
Cdk2 and Cdk4
Cdk2 immunohistochemistry showed labeling of small numbers of BCs nuclei in 6 cases (Fig. 1J) ; 5 of these cases were in the pediatric age group (i.e. younger than 8 years of age) (Table 3 ). There was no labeling of DNs or of neurons in adjacent or control cortex for cdk2. Cdk4 staining showed strong labeling of BCs in all but 1 FCD case (Figs. 1E, 2C,  D) , with a high proportion of labeled nuclei, particularly in the pediatric cases. In addition, cdk4 antibody, in contrast with other cell cycle proteins, demonstrated coarse cytoplasmic labeling in a proportion of BCs and DNs, particularly in adult cases (Figs. 1F, 2D ). The immunoreactivity for cdk4 was greater in FCD tissue than in the adjacent more normal cortex. In control pediatric and adult temporal lobe cases from patients with refractory epilepsy and adult nonepilepsy temporal lobe cdk4 and cdk2 showed labeling of occasional small glial cells in the cortex and white matter.
p53 and Checkpoint 2 p53 immunohistochemistry showed moderate numbers of positively labeled BC nuclei in the majority of FCD cases from a wide age range, but no labeling of DNs was observed (Figs. 1M, 2F, 3 ). There was labeling of BCs both in the cortex and the white matter with p53, but in 2 cases an impression of increased frequency of immunopositive cells located in the deeper white matter was noted. p53 was also observed to label multinucleated BCs (Fig. 1M) . Labeling with antibodies to phospho-chk2 was positive in the region of dysplasia in only 4 cases, with weak cytoplasmic labeling of infrequent BCs. In 2 cases, labeling of reactive-appearing glial cells in the vicinity of the dysplasia and in close proximity to the BCs was noted (Table 3; Fig. 1N ). Control pediatric and adult temporal lobe cases from patients with refractory epilepsy and adult nonepilepsy temporal lobe showed very occasional labeling of small glial cells for p53 and chk2 but no neuronal staining.
Study of Cell Cycle Proteins in Normal Postnatal Brain Series
The cell cycle proteins in a series of 6 normally developing postnatal brains from age 37 weeks_ gestation up to 15 months (37 weeks_ gestation and 1 day, 13 days, 15 days, 10 months, and 15 months postterm) were examined. Mcm2 and geminin antibodies showed nuclear labeling of prominent numbers and clusters of small, undifferentiated cells with angular, ovoid, or fusiform nuclei in the periventricular region and scattered singly throughout the white matter interstitium and cortical layers up to 13 days. From 15 days to 15 months there was a progressive reduction in the numbers of these positive cells in these regions. Nonphosphorylated Rb immunolabeling showed a distribution and staining pattern similar to those for geminin in the early postnatal cortex, with a marked reduction in the numbers of positive cells from 10 months onward, when only occasional positive small nuclei in the cortex were observed; this process was paralleled by occasional nuclear labeling of mature pyramidal neurons for Rb in the older postnatal cortex. Cdk4 showed nuclear positivity in small numbers of single small cells in the periventricular region, white matter, and cortex at all ages. Only very occasional cells were seen to label with anti-phosphorylated Rb (Ser 795 ) and anti-p53 in any of the zones at any of the ages. Cyclin D1 labeling highlighted small glial and satellite cells in the white matter and cortex, more prominent from 10 months onward, as seen in adult cortex (Fig. 1G) ; labeling of mature pyramidal cells was not seen. With cyclin E immunohistochemistry in the brains up to 15 days old, nuclear labeling of mature neurons in the subcortical white matter, layer I, and occasional small cells in the periventricular region was observed but not in the 10-and 15-month-old cases. No cells with the morphology of BCs were observed at any stage in the postnatal study group.
DISCUSSION
The etiology of FCD is unknown. It is generally considered to be developmental in origin. It is a sporadic condition that may affect any lobe and theories regarding its etiopathology include a somatic mutation in a precursor or progenitor cell during corticogenesis. However, there is some experimental and clinical data to support the possibility that cerebral-cortical injury or insult, including early trauma, could trigger a cascade of events leading to the FCD-like phenotype (15Y17). Cell cycle arrest in FCD could plausibly be triggered by a variety of local stress factors during development or early life including hypoxia, nutrient or growth factor deficiency, DNA damage, abnormal cell-cell or cell-matrix contacts, or seizures themselves. Indeed, FCD may have multiple etiologies. BCs are one of the characteristic cell phenotypes in FCD. They are unique to this type of cortical malformation and the defining feature of FCDIIB (2) , and many recent studies have focused on the etiopathology of this cell type as a potential key to understanding the nature of FCD and associated epileptogenesis (1, 9Y11, 18) .
One intriguing possibility that has been raised recently is whether BCs are involved in an abnormal cell cycle. For example, a recent study of cyclin A2 and cdk1 in BCs in FCD showed reduced expression levels that were interpreted as possible failure of cells to leave the S/G 2 phase (19) . Normal cells respond to withdrawal of growth factors by arresting in G 0 (quiescence). Cell stresses, including DNA damage, excessive mitogenic, or cytotoxic stimuli can also lead to a cascade of events resulting in withdrawal of proliferating cells from the cell cycle (Bstress-induced senescence[) (20) (Fig. 4) . p53, retinoblastoma tumor suppressor proteins (Rb), and cell cycle checkpoints, such as chk2, have been shown to play critical roles in induction of senescence (20, 21) . Rb in its active hypophosphorylated form represses cell cycle progression and results in early G 1 phase arrest.
We have previously identified high expression levels of mcm2 protein in BC nuclei, suggesting that these cells may represent a pool of less differentiated cells that have retained proliferative potential (4). Mcm proteins are recruited to DNA replication origins and bind to chromatin in a cell-cycle dependent manner (22) . Normally mcm proteins are tightly bound in late mitosis and G 1 while being removed and exported from the nucleus in S and G 2 phases. In our initial study, as has also been noted in previous studies of FCD (23) , only very occasional BCs were observed to label with more Bconventional[ proliferation markers as Ki67 and mitotic figures were not identified. This observation suggests that few BCs actually progress through G 1 to complete the cell cycle. Therefore, in this study using an extended series of FCDIIB surgical cases from 3 UK centers performing epilepsy surgery, we investigated the expression of cell cycle proteins important in the transition through G 1 to S phase to try to better determine cell cycle function in BCs.
By using immunohistochemistry for geminin protein, in the current study we lend support to the hypothesis that BCs do not complete the cell cycle. As with Ki67, the fraction of BCs labeling with 2 antibodies recognizing geminin was consistently far lower compared to mcm2 labeling, for which up to 100% of BCs were positive (4) . Geminin is present in the S, G 2 , and M phases of the cell cycle and inhibits DNA replication licensing by binding to cdt1 and preventing loading of mcm2 onto DNA. These findings reinforce this view that probably only a small proportion of BCs could progress through the G 1 phase, beyond the restriction point, to enter S phase and potentially complete cell division. We demonstrated the presence of unphosphorylated active Rb in BC nuclei in the majority of FCD cases, which may implicate this protein as coordinating proliferative arrest. In the FCD cases studied, activated phospho-chk2 expression was not present in the BC or DN nuclei. However, some immunopositivity for chk2 was noted in 5 cases in the vicinity of dysplasia in the cytoplasm of cells with BC morphology and in reactive glial cells with multiple processes, some in proximity to negatively labeled BCs, although the significance of this cytoplasmic labeling is uncertain (24) . Intracellular accumulation of p53 targets p21, inhibiting cdk2 and maintaining a cell in arrested cell cycle (25) . In the present study nuclear labeling of p53 was noted in a proportion of BC nuclei in most FCD cases. Cdk2 expression levels were low. This raises the possibility that activation of p53 may be also be a factor contributing to an early G 1 arrest of BC proliferation.
In contrast, cell arrest in late G 1 is associated with expression of cyclins D and E and may manifest as Bhypertrophic cell senescence[ in which progression of the cycle is blocked, although progressive cell enlargement mediated by mammalian target of rapamycin (mTOR) and protein synthesis may continue uncurtailed (26) . Recent studies in FCD have confirmed activation of pathways, including phosphatidylinositol 3-kinase PIK3 and mTor (9, 10, 27, 28) , which have regulatory effects on cell growth and protein synthesis and are implicated in the observed cytomegaly in both neurons and BCs in these lesions. In addition, altered expression of molecules in BCs and DNs, as pAKT (28) , in addition to A-catenin (11) in the wnt signaling pathway, have been previously reported in FCD series and may have influence on cell cycle regulation as they are also involved in the regulation and/or degradation of cyclins D and E (21) . Based on these observations, the possibility of late G 1 arrest occurring in BCs also merited further exploration.
Progressive phosphorylation of Rb controls progression through the restriction point (also known as the irreversible commitment point [29] ) of the G 1 phase toward S phase entry (30, 31) . By using 2 well-characterized antibodies specific for Rb phosphorylation sites 795 and 807/811, expression of phospho-Rb was limited to a few BCs in 5 of the FCD cases, which would overall support a lack of cyclin D/cdk4 or cyclin E/cdk2 activity. We also show a striking lack of cyclin E expression in BC nuclei with very rare immunopositive cells, often only weakly stained. Cyclin E, which activates cdk2, is tightly regulated (32) , with expression being high in the late G 1 /S phase of the cell cycle, but levels are low in quiescent cells (33) . Nuclear cdk2 expression was noted in only a small number of BCs in 6 FCD cases, with 2 of these cases (cases 2 and 13) showing focal immunopositivity for phospho-Rb in BCs. Taken together the results of this analysis provide little evidence for cyclin E expression or activity in BCs and consequent progression through G 1 and the restriction point. There was also no convincing evidence for BC nuclear labeling for cyclin D with only 2 cases showing weak cytoplasmic labeling. A lack of labeling was noted in the DN component but strong cytoplasmic labeling of morphologically normal neurons and glia was present in the adjacent cortex as well as in the dysplastic region. Cyclin D1 nuclear transport (34) is facilitated by glycogen synthase kinase (GSK) 3A and, interestingly, a reduction of GSK3 activity has been shown in tuberous sclerosis complex (TSC) 1-deficient cells (35) and BCs in FCD (11) .
In contrast to cyclin D1, strong labeling of BC nuclei with cdk4 was noted, particularly in the pediatric FCD cases, whereas cytoplasmic granular labeling was noticed in the adult FCD cases. Cdk4 is predominantly located in the cytoplasm of differentiated cells (34) with nuclear expression associated with proliferation or progenitor cells. The high expression levels in BCs would suggest induction of cell cycle pathways, but the relative lack of its activator cyclin D1 could be the rate-limiting factor for progression through the early G 1 phase. In conclusion, despite the hypertrophied morphology of BCs, our findings of low expression of cyclins and phospho-Rb in BCs does not support a late G 1 phase or hypertrophic arrest (26) (Fig. 4) . Based on our observations, cell arrest at an earlier point of the G 1 phase of the cell cycle seems to be more plausible, although the mechanisms leading to this need to be further explored; stress-induced or physiologic cell senescence is a possible explanation.
It has been increasingly recognized that many molecules controlling cell division also have important regulatory functions in differentiation and the acquisition of neuronal identity (6), including geminin (36) , cyclin E (37), cyclin D1 (6), and unphosphorylated Rb (38) , and there are data indicating that phospho-Rb plays a crucial role in astrocyte differentiation (6) . In the present study the low levels of geminin, cyclins D1 and E, and phospho-Rb expression may also be relevant to lack of lineage specification and differentiation in the phenotypically immature BCs and are worthy of further investigation.
Furthermore, FCD may show progressive pathologic changes over time. For example, in pediatric cohorts FCD is often multilobar, whereas in adults it is often much less extensive, often confined to 1 or 2 gyri (1). Although this finding may reflect greater severity of the disease in patients presenting early in life, evolving or maturing pathologic changes over time cannot be excluded. For example, in adults neuronal density is relatively reduced in FCD (39) . In contrast, in pediatric patients, FCD is relatively hypercellular compared with histologically normal adjacent cortex (40) . Reactivation of cell cycle proteins, including cyclin D1 and E in Alzheimer disease is associated with activation of cell death cascades (8, 13, 34) . Cdk4 induction has also been shown to have a critical role in delayed neuronal death in models of ischemia (41) . Age-dependent expression patterns of cyclin E and D1 and cdk4 observed in the dysplastic regions may all be of relevance to progressive changes in FCD, including increased susceptibility to apoptotic cellular pathways, although this suggestion requires further verification.
There are several limitations to this study. It is a semiquantitative immunohistochemistry study using both surgical and postmortem case and control tissues with differences in fixation and processing times, which could influence antigen detection. Age-dependent effects could also influence cell cycle progression in BCs, which should to be taken into account. In our small series of normal developing brains there was clear age-dependent expression of geminin, Rb, and cyclin E in the white matter or cortex. Furthermore, our results have been interpreted in the framework of a normal cell cycle; from previous studies of FCD, activation of other pathways (9Y11, 29) may Bcross-talk[ with cell cycle regulatory pathways, rendering an abnormal cell cycle state in BCs. In addition, our knowledge of the effects of pathologic states and events, including seizures, on the expression of cell cycle proteins is as yet rudimentary. Reactivation of cell cycle proteins could occur in refractory epilepsy, independent of any maldevelopmental process. Cell cycle protein expression in epilepsy requires further exploration.
In conclusion, dysregulation of cell cycle proteins in abnormal BCs in FCD may be a primary abnormality influencing the lack of cell maturity, cell cycle progression, and eventual determination of cell fate. These features may affect the physiologic properties of these cells and contribute to epilepsy. This initial study also suggests variation in expression between pediatric and adult cases and between cell types, which requires further study to explore the possible time points and potential avenues for therapeutic interventions that might halt or even reverse the pathologic process.
